Gene Discovery News: Breaking Gene Discovery News, Comments and Articles. - Page: 5

22:34 EST 1st March 2015 | BioPortfolio

Gene Discovery News - Page: 5RSS

Read the latest Gene Discovery News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Gene Discovery.

Search or Follow Our Gene Discovery - Page: 5 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Gene Discovery - Page: 5 News.

Showing "gene discovery" News Articles 101 to 125 of 6,900+

Wednesday 25th February 2015

Cobra and The University of Manchester Receive £217K Innovate UK / BBSRC Funding

Cobra Biologics and The University of Manchester have been awarded collaborative funding of £217K as one of only 23 projects which will share almost £20M from the Innovate UK / Biotechnology and Biological Sciences Research Council (BBSRC...

Genetic Technologies Appoints Eutillio Buccilli as Chief Executive Officer

MELBOURNE, AUSTRALIA -- (Marketwired) -- 02/26/15 -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") is pleased to advise that Mr. Eutillio Buccilli has been appointed Chief Executive Officer of the Company following the resignation of Ms. Alison Mew which was effective 31 December 2014. Mr. Eutillio Buccilli Mr. Buccilli joined the Company in Ju...

DS Healthcare Announces Discovery Of New Peptide

Pompano Beach, Fla., Feb. 26, 2015 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc. (DSKX), today announced that it has initiated synthesis of a new peptide for the treatment of hair loss and related conditions. The peptide works directly on the FGF5 (Fibroblast growth factor 5) pathway. Suppression of FGF5 has been shown to extend the anagen cycle of hair growth and causes more hair growth and long...

IU researchers identify pancreatic cancer patients who benefit from personalized treatment

(Indiana University) Cancer researchers at Indiana University report that about 15 percent of people with pancreatic cancer may benefit from therapy targeting a newly identified gene signature.

Discovery about beliefs could prove useful in addiction treatment, researchers say

(Virginia Tech) Virginia Tech Carilion Research Institute scientists have discovered that beliefs can regulate the effects of nicotine on the human brain.

Gene discovery sheds light on causes of rare type of dwarfism

(University of Edinburgh) A gene linked to a type of dwarfism has been identified by researchers at the University of Edinburgh. The development will help to provide better diagnoses for those families affected.

Living in the genetic comfort zone

(University of Veterinary Medicine -- Vienna) Scientists at the Vetmeduni Vienna found that, despite underlying genetic differences, two separate strains of fruit flies had a very similar gene expression pattern at 18°C. This effect of 'canalization...

Novel gene variants found in a difficult childhood immune disorder

(Children's Hospital of Philadelphia) Genomics researchers analyzing a rare, serious immunodeficiency disease in children have discovered links to a gene crucial to the body's defense against infections. The finding may represent an inviting target f...

bluebird bio Reports Fourth Quarter and Full Year 2014 Financial Results and Recent Operational Progress

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2014. “Over the last year, bluebird b...

Alnylam to Webcast Presentation at Cowen & Company 35th Annual Health Care Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Cowen and Company 35th Annual Health Care Conference on Wednesday, March 4, 2015 at 10:00 a.m. ET at the Boston Marriott Copley Place Hotel in Boston. A live audio webcast of the presentat...

Differential DNA mismatch repair underlies mutation rate variation across the human genome

Cancer genome sequencing has revealed considerable variation in somatic mutation rates across the human genome, with mutation rates elevated in heterochromatic late replicating regions and reduced in early replicating euchromatin. Multiple mechanisms...

Agenus to Present at the Cowen and Company 35th Annual Health Care Conference

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing a broad portfolio of checkpoint modulators (CPMs) and heat shock protein-based vaccines, as well as immune adjuvants, today announced that the Company will present at the Cowen and Company 35th Annual Health Care Conference on Monday, March 2nd at 3:30 p.m. Eastern Time. The conference will...

Pancreatic cancer has four distinct types

Researchers have found that pancreatic cancer can be split into four unique types, a discovery that could be used to improve treatments for the disease, according to a study published in Nature.1 The international team of scientists, including Cance...

After cuts, Pfizer looks to gene therapy, immuno-oncology

Pfizer Inc. (NYSE:PFE) said it will cut an undisclosed number of R&D jobs at its Cambridge, Mass., and Collegeville, Pa., facilities. Pfizer spokesperson Dean Mastrojohn declined to say which R&D areas would be cut. The company plans to reallocate re...

Scientists Identify Gene that Could Prevent Cross-pollination

Scientists at the University of Guelph identified a gene that could block genetically modified crops from cross-contaminating conventional crops. According to Sherif Sherif, lead author of the study, this discovery may put down arguments against GM food crops. Sherif and team found a gene that codes for a protein that naturally allows some plants t...

Response of GM Maize (DKC6575) Under Drought

Researchers from University of Parma and Sapienza University in Rome conducted a comparative study on the response and gene expression of GM maize variety, DKC6575, with its near-isogenic non-GM line, Tietar under drought conditions. The response and gene expression levels of both varieties were examined. GM maize was further analyzed for the chang...

Tolero Pharmaceuticals Receives EMA Orphan Drug Designation for Alvocidib for the Treatment of Acute Myeloid Leukemia

SALT LAKE CITY, Feb. 25, 2015 /PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that the European Medicines Agency (EMA) has granted orphan drug designation for alvocidib for the treatment of patients with acute myeloid leukemia (AML). Alvocidib is in clinical development for patients with relapsed/...

Highland Therapeutics to Present at Cowen and Company 35th Annual Health Care Conference

Highland Therapeutics Inc. (“Highland”), a pharmaceutical company, today announced that the Company will present at the Cowen and Company 35th Annual Health Care Conference at the Boston Marriott Copley Place Hotel in Boston, MA. Highland’s presentation is scheduled for Monday, March 2, 2015 at 9:00am EST. Nelson F. Isabel, Chief Financial O...

Ardelyx Reports Fourth Quarter and Full Year 2014 Financial Results

FREMONT, Calif., Feb. 25, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced financial results for the fourth quarter and twelve months ended December 31, 2014. "2014 has been a highly productive year at Ardelyx, with advancements in the clinical program for t...

Sangamo BioSciences Announces Presentation At The Cowen And Company 35th Annual Health Care Conference

RICHMOND, Calif., Feb. 25, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 8:40 am ET on Wednesday, March 4, 2015, at the 35th Annual Cowen and Company Health Care Confer...

TRADE NEWS: Agilent Technologies Introduces OneSeq to Streamline Cytogenetic Research

Assay Allows Scientists to Identify Mutations and Copy Number Changes in a Single Reaction Agilent Technologies Inc. (NYSE:A) today introduced OneSeq, the industry’s first all-in-one target enrichment product for next-generation sequencing. OneSeq is designed to detect and analyze copy number variations, loss of heterozygosity, and mutations in a ...

Cystic fibrosis discovery may lead to new treatment strategy, help patients breathe easier

A team led by UC San Francisco professor of medicine John Fahy, MD, has discovered why mucus in the lungs of people with cystic fibrosis (CF) is thick, sticky and difficult to cough up, leaving these patients more vulnerable to lung infection.

Recursion Pharmaceuticals Wins $1.5M NIH Grant for Rare Disease Drug Discovery

Recursion Pharmaceuticals, an emerging biotech company today announced a $1.46M award from the National Institutes of Health (NIH) via the National Center for Accelerating Translational Sciences (NCATS). Just over half of the award is available in the first year; the rest will come through in year two pending availability of funds and project progress. The...

Jounce Therapeutics to Present at the Cowen and Company 35th Annual Health Care Conference

Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies, today announced that Richard Murray, Ph.D., chief executive officer, will present a company overview at the Cowen and Company 35th Annual Healthcare Conference on Tuesday, Mar. 3 at 9 a.m. ET at The Boston Marriott Copley Pla

ArQule to Report Fiscal 2014 Financial Results on March 4, 2015

ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the fiscal 2014 year-end and fourth quarter on Wednesday, March 4, 2015 at 7:00 a.m. eastern time. The Company will hold a conference call at 9:00 a.m. eastern time that day to discuss these results. Conference Call and Webcas...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks